Lupin to acquire VISUfarma for €190 million, enhancing its European presence and ophthalmology portfolio with over 60 eye ...

Lupin's subsidiary, Nanomi BV, is set to acquire VISUfarma BV for 190 million euros, aiming to enhance its European market presence. The acquisition will broaden Lupin's specialty franchise in ...

Drugmaker Lupin will acquire Dutch firm VISUfarma in a transaction that pegs the enterprise value of the Amsterdam-based ...

Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN), today announced ...

Indian pharmaceutical company, Lupin, is set to acquire Amsterdam-based ophthalmology firm VISUfarma for €190 million, expanding its European presence and specialty portfolio.

The company's wholly-owned subsidiary, Nanomi BV has signed a definitive agreement for the acquisition of VISUfarma BV, a ...

Lupin subsidiary acquires VISUfarma for 190 million euros, expanding its European presence and ophthalmology portfolio. Deal ...

Lupin announced its wholly owned subsidiary, Nanomi B.V. (Nanomi), has signed a definitive agreement for the acquisition of VISUfarma B.V. (VISUfarma), a portfolio company of global healthcare ...

Mumbai-based pharmaceutical major Lupin will acquire Netherlands-based VISUfarma B.V. for an enterprise value of EUR 190 ...

VISUfarma B.V. is headquartered in Amsterdam and it is a specialty pharmaceutical company focused on ophthalmology.

VISUfarma has a portfolio of more than 60 branded ophthalmology products and established operations across Italy, the UK, ...